Cardiovascular Outcomes and Efficacy of the PCSK9 Inhibitor Evolocumab in Individuals With Type 1 Diabetes: Insights From the FOURIER Trial
Intensive LDL-C lowering may provide substantial clinical benefit in individuals with T1DM and ASCVD. Additional randomized controlled cardiovascular outcomes trials are needed in this population.
Authors
- Xinhui Ran
- Basil S. Lewis (ORCID: https://orcid.org/0000-0001-5604-6399)
- J. Antonio G. López (ORCID: https://orcid.org/0000-0001-8604-5549)
- Gabriel Paiva da Silva Lima (ORCID: https://orcid.org/0000-0001-8073-719X)
- Marc S. Sabatine (ORCID: https://orcid.org/0000-0002-0691-3359)
- Jyothis T. George (ORCID: https://orcid.org/0000-0002-5299-775X)
- Yehuda Handelsman (ORCID: https://orcid.org/0000-0001-7830-0247)
- Huei Wang (ORCID: https://orcid.org/0000-0002-9903-1979)
- E. Magnus Ohman (ORCID: https://orcid.org/0000-0002-6249-4988)
- Robert P. Giugliano (ORCID: https://orcid.org/0000-0003-4110-7675)
- Maria Laura Monsalvo (ORCID: https://orcid.org/0000-0002-4113-9418)
- Gaetano Maria De Ferrari (ORCID: https://orcid.org/0000-0003-4940-0876)
- Ioanna Gouni‐Berthold
- Prakash Deedwania (ORCID: https://orcid.org/0000-0002-5652-9347)
- Lawrence A. Leiter (ORCID: https://orcid.org/0000-0002-1040-6229)
- Yu Mi Kang (ORCID: https://orcid.org/0000-0002-6272-0666)
Institutions
- Brigham and Women's Hospital (US)
- St. Michael's Hospital (CA)
- Amgen (United States) (US)
- Azienda Ospedaliera Citta' della Salute e della Scienza di Torino (IT)
- Tarzana Treatment Centers (US)
- Carmel Medical Center (IL)
- University Hospital Cologne (DE)
- Thrombolysis in Myocardial Infarction Study Group (US)
- California State University, Fresno (US)
Publication Details
- Journal
- Diabetes Care
- Published
- 2025-06-22
- DOI
- https://doi.org/10.2337/dc25-0942
- Citations
- 3
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 6.02
Funders
- Division of Diabetes, Endocrinology, and Metabolic Diseases